Immuron Ltd (ASX:IMC), makers of Travelan tablets for the prevention of travellers’ diarrhoea, has launched Travelan through CVS Pharmacy (NYSE:CVS) in the U.S.
CVS Pharmacy is the second largest pharmacy chain in the United States after Walgreens (NASDAQ:WBA).
Travelan will be available in nearly 1,000 CVS pharmacies across the US by late May 2016.
The initial order will be for several thousand units which will be supported by targeted pull-through marketing initiatives for the product’s introduction into the CVS retail channel.
Travelan is marketed as a dietary supplement in the U.S., allowing it to be sold in pharmacies, drug stores and general stores.
In February 2016, Immuron received a cash refund of A$1,469,763 in the form of research and development tax concessions for the 2015 financial year.
In February, the company also executed a funding agreement with a New York-based investment fund to provide A$1.7 million in funding to Immuron.
Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.